Loading...
Market
What will be the outcome of Pfizer and BioNTech's next trial for the COVID-19-Flu vaccine by the end of 2024?
2
Resolution / Starting Odds
Meets all objectives • 25%
Meets some objectives • 25%
Meets no objectives • 25%
Trial postponed or canceled • 25%
Official trial results published by Pfizer and BioNTech
Story
Pfizer and BioNTech's COVID-19-Flu Vaccine Faces Setback with 2.4% Decline
Aug 16, 2024, 01:30 PM
Pfizer and BioNTech have updated their mRNA-based combination vaccine program against influenza and COVID-19 for individuals aged 18-64. The COVID-19-flu combination drug met one of two trial objectives, but showed a lower immune response against influenza B. This setback in their late-stage trial has resulted in a 2.4% pre-market decline in BioNTech's stock. The combination vaccine's partial success highlights ongoing challenges in developing effective vaccines against multiple strains.
View original story
Similar markets
Positive • 33%
Neutral • 33%
Negative • 33%
Trial Resumed • 33%
Trial Terminated • 33%
Trial Modified • 34%
No change in safety guidelines • 25%
Minor safety warning issued • 25%
Major safety warning issued • 25%
Vaccine approval revoked • 25%
Vaccine approved and in use • 25%
Vaccine in clinical trials • 25%
Vaccine in development but not in trials • 25%
No vaccine development • 25%
Significant Improvement • 33%
No Change • 33%
Significant Adverse Effects • 34%
Phase 2 • 25%
Phase 3 • 25%
Trial termination • 25%
No announcement • 25%
Significant survival improvement • 25%
Partial survival improvement • 25%
No significant change • 25%
Deterioration • 25%
Effective • 25%
Moderately Effective • 25%
Ineffective • 25%
Halted • 25%
Successful with significant improvement in survival rates • 25%
Successful with moderate improvement in survival rates • 25%
No significant improvement in survival rates • 25%
Trial halted due to adverse effects • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%